Preventing and treating eclamptic seizures

BMJ

Volumn 326, Issue 7379, 2003, Pages 50-

  Moran, Neil F ^a   Moore, Ben ^b   Collins, Richard ^b  

^a Mahatma Gandhi Memorial Hospital   (South Africa)

^b Hospitali Teule ^*  (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; ANTICONVULSIVE AGENT;

BREATHING RATE; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; ECLAMPSIA; HUMAN; LETTER; MATERNAL MORTALITY; PREECLAMPSIA; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REFLEX; TREATMENT OUTCOME; URINE VOLUME; WORKLOAD; FEMALE; NOTE; PREGNANCY; SEIZURE;

ANTICONVULSANTS; FEMALE; HUMAN; MAGNESIUM SULFATE; PRE-ECLAMPSIA; PREGNANCY; SEIZURES; HUMANS;

EID: 0037417690     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.326.7379.50     Document Type: Letter

References (4)

1. Roberts JM, Villar J, Arulkumaran S. Preventing and treating eclamptic seizures. BMJ 2002; 325: 609–610
2. Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the collaborative eclampsia trial. Lancet 1995; 345: 1455–1463
3. The Magpie Trial Collaboration Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877–1890
4. Roberts JM, Vilar J, Arulkumaran S. Preventing and treating eclamptic seizures. BMJ 2002; 325: 609–610